<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03366571</url>
  </required_header>
  <id_info>
    <org_study_id>D161100002716003</org_study_id>
    <nct_id>NCT03366571</nct_id>
  </id_info>
  <brief_title>Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy</brief_title>
  <official_title>Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who have completed 3 years follow-up of the past Beijing Science and Technology
      Commission Research will receive another 2-years anti-viral therapy. Patients will be
      assessed at baseline and every six months for blood cell count, liver function test, HBVDNA,
      AFP, prothrombin time, liver ultrasonography, and Fibroscan. CT or MRI and endoscopy will be
      performed at baseline and 3 years. At the end of the study, the cumulative rate of clinical
      hepatic hard endpoint will be calculated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have completed 3 years follow-up of the past Beijing Science and Technology
      Commission Research will receive another 2-years anti-viral therapy. Patients will be
      assessed at baseline and every six months for blood cell count, liver function test, HBVDNA,
      AFP, prothrombin time, liver ultrasonography, and Fibroscan. CT or MRI and endoscopy will be
      performed at baseline and 3 years. At the end of the study, the cumulative rate of clinical
      hepatic hard endpoint will be calculated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative rate of liver decompensation and/or hepatic carcinoma and/or liver related death</measure>
    <time_frame>5 years</time_frame>
    <description>Cumulative rate of liver decompensation (including ascites,hepatic encephalopathy,Gastrointestinal hemorrhage)，and/or hepatocellular carcinoma， and/or liver related death after 5 years of antiviral treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBV-DNA undetectable rate</measure>
    <time_frame>5 years</time_frame>
    <description>HBV-DNA undetectable rate after 5 years of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of transient elastography</measure>
    <time_frame>5 years</time_frame>
    <description>Decrease of transient elastography after 5 years of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg seroconversion rate</measure>
    <time_frame>5 years</time_frame>
    <description>HBeAg seroconversion rate after 5 years of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg seroconversion rate</measure>
    <time_frame>5 years</time_frame>
    <description>HBsAg seroconversion rate after 5 years of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of Child-Pugh score</measure>
    <time_frame>5 years</time_frame>
    <description>Decrease of Child-Pugh score after 5 years of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of MELD score</measure>
    <time_frame>5 years</time_frame>
    <description>Decrease of MELD score after 5 years of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of life Quality assessed by SF-36</measure>
    <time_frame>5 years</time_frame>
    <description>Improvement of life Quality assessed by SF-36 after 5 years of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of life Quality assessed by EQ-5D</measure>
    <time_frame>5 years</time_frame>
    <description>Improvement of life Quality assessed by EQ-5D after 5 years of antiviral treatment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Anti-viral therapy group</arm_group_label>
    <description>Subjects who have completed the 3 years research &quot;Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non anti-viral therapy group</arm_group_label>
    <description>History study from literature</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleos(t)ide Analogues</intervention_name>
    <description>Entecavir 0.5mg daily for no less than 5 years ;Lamivudine:100mg qd daily for no less than 5 years; Adefovir Dipivoxil:10mg daily for no less than 5; years;telbivudine:600mg qd daily for no less than 5 years; or their combination therapy for no less than 5 years</description>
    <arm_group_label>Anti-viral therapy group</arm_group_label>
    <other_name>Baraclude , et al</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum,plasma and DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The HBV-related chronic hepatitis /cirrhosis patients who have completed 3 years follow-up
        of the past Beijing Science and Technology Commission Research.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have participated in the research funded by Beijing science and
             Technology Commission and have completed 156 weeks follow-up.

          -  Patients comply with the requirements of the trail voluntarily

          -  Written informed consent

        Exclusion Criteria:

          -  Pregnant woman or patient with severe disease

          -  Patients with poor adherence to the study

          -  Patients not suitable for the study evaluated by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong J Jia, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong J Jia, Doctor</last_name>
    <email>jiamd@263.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jialing Zhou, doctor</last_name>
    <phone>010-63138665</phone>
    <email>zhoujialing11@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anlin Ma, Doctor</last_name>
      <phone>13910253710</phone>
      <email>maanlinjc@163.com</email>
    </contact>
    <investigator>
      <last_name>Anlin Ma, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyuan Xu, Doctor</last_name>
      <phone>13001185762</phone>
      <email>xiaoyuanxu6@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoyuan Xu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing 302 Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng G Chen</last_name>
      <email>bjchen302@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Feng G Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Ditan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Xie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Y Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guo H Ding, Doctor</last_name>
      <phone>8613699119545</phone>
      <email>lilei_1978@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing X Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PeKing University People's Hopital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Ma, Doctor</last_name>
      <phone>8613671090481</phone>
      <email>mahui_wj@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2016</study_first_submitted>
  <study_first_submitted_qc>December 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2017</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Jidong Jia</investigator_full_name>
    <investigator_title>Director of Liver Research Center</investigator_title>
  </responsible_party>
  <keyword>Liver Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

